I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Defense Medical Research and Development Program (DMRDP)

Joint Program Committee 6 (JPC-6)/

Combat Casualty Care Research Program (CCCRP)

En Route Care Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-21-DMRDP-ERCA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), March 31, 2021
- Invitation to Submit an Application: May 13, 2021
- Application Submission Deadline: 11:59 p.m. ET, June 23, 2021
- End of Application Verification Period: 5:00 p.m. ET, June 28, 2021
- Peer Review: August 2021
- Programmatic Review: October 2021

This Program Announcement must be read in conjunction with the General Application Instructions, version 601. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ................................................................. 1

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY ............. 3

II.A. Program Description ........................................................................................................ 3
  II.A.1. FY21 DMRDP JPC-6/CCCRP ERCA Focus Areas .............................................. 3
  II.A.2. Award Background ................................................................................................. 4

II.B. Award Information ......................................................................................................... 7

II.C. Eligibility Information ..................................................................................................... 9
  II.C.1. Eligible Applicants .................................................................................................. 9
  II.C.2. Cost Sharing ........................................................................................................... 10
  II.C.3. Other .................................................................................................................... 10

II.D. Application and Submission Information ................................................................. 10
  II.D.1. Address to Request Application Package ............................................................ 11
  II.D.2. Content and Form of the Application Submission ................................................ 11
  II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM) ................................................................. 31
  II.D.4. Submission Dates and Times ................................................................................. 31
  II.D.5. Funding Restrictions .............................................................................................. 32
  II.D.6. Other Submission Requirements ........................................................................... 33

II.E. Application Review Information ................................................................................... 33
  II.E.1. Criteria ................................................................................................................... 33
  II.E.2. Application Review and Selection Process ............................................................ 37
  II.E.3. Integrity and Performance Information .................................................................. 37
  II.E.4. Anticipated Announcement and Federal Award Dates .......................................... 38

II.F. Federal Award Administration Information ............................................................... 38
  II.F.1. Federal Award Notices ........................................................................................... 38
  II.F.2. Administrative and National Policy Requirements ................................................ 39
  II.F.3. Reporting ................................................................................................................ 39

II.G. Federal Awarding Agency Contacts .......................................................................... 40
  II.G.1. CDMRP Help Desk ............................................................................................... 40
  II.G.2. Grants.gov Contact Center .................................................................................... 40

II.H. Other Information ......................................................................................................... 40
  II.H.1. Program Announcement and General Application Instructions Versions .......... 40
  II.H.2. Administrative Actions .......................................................................................... 40
  II.H.3. Application Submission Checklist ......................................................................... 43

APPENDIX 1: ACRONYM LIST ............................................................................................ 45

APPENDIX 2: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS ........................................................................... 47
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2021 (FY21) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The US Army Medical Research and Development Command (USAMRDC) Congressionally Directed Medical Research Programs (CDMRP) provides Defense Medical Research and Development Program (DMRDP) execution management support for DHP core research program areas, including the JPC-6/CCCRP. This Funding Opportunity Announcement and subsequent awards will be managed and executed by the CDMRP with strategic oversight from the JPC-6/CCCRP.

The JPC-6/CCCRP is one of five core research program areas within the DHP. The JPC-6/CCCRP is a committee of Department of Defense (DoD) and non-DoD medical and military technical experts in combat casualty care-related program areas. The JPC-6/CCCRP strives to optimize survival and recovery from combat-related or trauma-induced injury in current and future operational scenarios. This is being accomplished through the development of knowledge and materiel products for the acute and early management of combat-related or trauma-induced injury, including point-of-injury, en route, and forward surgical care. Products developed by JPC-6/CCCRP-supported research are applied in-theatre and within the clinical facilities of the Military Health System (MHS). These solutions not only minimize the morbidity and mortality of combat-related injuries in Service members, they also are often translatable to the civilian healthcare system.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

II.A.1. FY21 DMRDP JPC-6/CCCRP ERCA Focus Areas

The JPC-6/CCCRP En Route Care (ERC) portfolio seeks to provide materiel and knowledge solutions to enable increased levels of care en route, mitigate negative effects of transportation or environmental extremes, provide patient care for longer time periods when delayed evacuation exceeds available capability and/or capacity, and extend provider capabilities in order to care for larger numbers of casualties.

The JPC-6/CCCRP has identified the following Focus Areas for funding under the FY21 DMRDP JPC-6/CCCRP ERCA. To meet the intent of the award mechanism, applications MUST specifically address at least one ERCA Focus Area. Research not aligned to at least one Focus Area will not be considered for funding. The ERCA Focus Areas are:
• Patient movement (e.g., ground, air, and sea transport)
  o Improved understanding of factors that influence clinical outcomes
  o Knowledge and materiel solutions to mitigate the negative impacts of patient movement
    • *Areas of interest include evidence-based safe transport and patient hand-off guidelines for critically injured patients (e.g., optimal altitude to prevent/reduce secondary trauma following hemorrhagic shock or traumatic brain injury, or vibration restrictions in post-operative patients) during and following a prolonged care scenario and documentation to improve outcomes and injury characteristics.*

• ERC in extreme cold environments (-25°F to -40°F or -32°C to -40°C)
  o Improved understanding of the factors that influence ERC performance and patient clinical outcomes
  o Knowledge and materiel solutions to improve ERC performance and patient outcomes in extreme cold environments
    • *Areas of interest include care provider cognitive and physical performance, durability and efficacy of ERC tools and materials, and environmental constraints imposed.*

• Mode, timing, and regulation of movement for ill, injured, resuscitated, and post-operative patients using manned or unmanned systems
  o Improved understanding of factors that influence clinical outcomes
  o Knowledge and material solutions to improve patient outcomes

**II.A.2. Award Background**

As the DoD prepares to address future battlefield, the outlook is framed in the recognition that the return of great power competition and multiplication of emerging threats portends changes in the pace, place, and complexity of war. Increased competition from technologically advanced and well-resourced peer and near-peer states, as well as global technological advances that enable emerging small- and non-state actors to generate threats, increasingly challenge United States deterrence, which is being contested in all domains.(References [Ref.] 1,2 below)

Simultaneously, changes in the Arctic landscape have exposed previously unreachable natural resources, increasing competition between Arctic nations, here in relatively close proximity, in a vast and inhospitable environment above latitude 66° 34' North.(Ref. 3, below) Consequently, the DoD’s strategic approach is to build Arctic awareness, enhance Arctic operations, and strengthen rules-based order in the region by re-invigorating Arctic warfighting capability through training exercises, strengthen regional partnerships, military capability gap
identification, and Arctic equipment testing to signal commitment to the Arctic region. (Ref. 3-5, below)

Decay of Arctic fighting acumen since the cold war has left a number of knowledge gaps currently being filled in a number of joint exercises in the region, (Ref. 6, below) but with a number of questions remaining for how best to provide combat casualty care and patient movement to support the Warfighter. Extreme Arctic conditions produce multitudinous challenges for flight operations, (Ref. 7, below) but patient care capability will also be severely impacted. For example, self-aid and buddy care will be complicated by the necessity for and presence of Arctic-wear. Moreover, tactical field care will necessarily include moving the casualty to a sheltered environment to mitigate a very rapid onset of hypothermia. Consequently, combat vehicles will likely become the first shelters of opportunity but with very limited space for the provision of critical care. As a consequence, hypothermia mitigation and treatment merit very high consideration.

Unfortunately, existing hypothermia prevention devices have limited ability to maintain core temperature at 37°C (98.6°F) for 2 hours at ambient temperatures of 22.5°C (72.5°F). (Ref. 8, below) It is unknown if these products will function or be completely ineffectual at maintaining body core temperature in lower ambient temperatures. Moreover, these products will likely be unable to restore body core temperature in casualties already suffering from marked hypothermia, particularly against frigid temperatures. Such equipment limitation is not restricted to temperature management devices; it remains unknown how extreme cold regions will affect function and employment of all en route care tools and supplies.

Beyond challenges imposed by extreme cold, locating and retrieving casualties is further complicated by Arctic topology and vast distances, much over the semi-frozen seas. Opening of sea lanes as a consequence of thinning sea ice has seen a remarkable increase in ship casualties, placing an extraordinary burden on search and rescue (SAR) capability. Between 2005 and 2019, the rate of casualties in Arctic circle waters for commercial ships with gross weight meeting or exceeding 100 tons increased 1366%; “Given the location of current U.S. Coast Guard operating bases, it could take Coast Guard aircraft several hours, and Coast Guard cutters days or even weeks, to reach a ship in distress or a downed aircraft in Arctic waters.” (Ref. 3, below) Constrained to providing care solely within the confines of the evacuation platform, en route care providers most often become task-saturated with very low numbers of casualties. (Ref. 9, below)

Patient movement by unmanned systems (ground, sea, and air) is of tremendous interest as a means to increase patient movement capability in hazardous and austere conditions if these systems can be made to sustain casualties during patient movement.

Automating patient movement and en route care is a research and development priority for all the services. (Ref. 10-12, below) Generally, the pathway includes: machine perception, reasoning, and intelligence; human-autonomous system interaction and collaboration; scalable teaming of autonomous systems; and testing, evaluation, validation, and verification. (Ref. 13, below) While great strides have been made toward increasing closed-loop systems to automate specific tasks much work remains to be accomplished toward coordinating and integrating multiple closed-loop systems.
References:


II.B. Award Information

The intent of this award mechanism is to support development of highly innovative materiel and knowledge products to drive critical combat casualty care capabilities to the Warfighter in highly mobile, austere, and extreme environments where evacuation capabilities may be significantly delayed or unavailable. (Ref. 2, above) This Funding Opportunity aligns with the recently published Committee on En Route Combat Casualty Care (CoERCCC) top 10 research priorities including: medical documentation, clinical decision support, patient monitoring, transfer of care, transport physiology, maintenance of normothermia, transport timing, intelligent tasking, commanders’ decision support, and unmanned transport. (Ref. 14, above) and focuses on research to knowledge and materiel to improve the en route care and patient movement from point of injury to definitive care by ground, air, and sea.

The solutions under this Funding Opportunity will not be limited to military use. Knowledge and materiel products developed will have applications in civilian environments as well. Natural disasters, explosive events, accidents, and mass shootings can generate a surge of casualties and complex injuries that can mirror those seen on the battlefield. Additionally, civilians, particularly those in rural areas, face challenges with delayed access to hospital-based care. While only 20% of all Americans live in rural areas, they account for more than 50% of all trauma-related fatalities. The majority of these individuals do not live within an hour of a Level I or II trauma center and could benefit from improvements in ERC. Solutions generated by this work will be applicable in civilian settings where mode of patient movement, environmental conditions, or traumatic condition are similar to the military use case.

We anticipate that projects funded under this award mechanism, as systematic application of knowledge or understanding, directed toward the production of useful materials, devices, and systems or methods, including design, development, and improvement of prototypes and new processes to meet specific requirements, will increase survivability from both combat-related and trauma-induced injuries.

The types of awards made under the Program Announcement will be assistance agreements. An assistance agreement is appropriate when the Federal Government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DoD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of
the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the 
award will identify the specific substantial involvement. Substantial involvement may include, 
but is not limited to, collaboration, participation, or intervention in the research to be performed 
under the award. The award type, along with the start date, will be determined during the 
negotiation process.

The anticipated total costs budgeted for the entire period of performance for an FY21 DMRDP 
JPC-6/CCCRP ERCA will not exceed $1.4 million (M). Refer to Section II.D.5, Funding 
Restrictions, for detailed funding information.

Awards will be made no later than September 30, 2022. For additional information refer to 
Section II.F.1, Federal Award Notices.

The CDMRP expects to allot approximately $1.8M of the FY21, $1.8M of the FY22, and 
$1.8M of the FY23 DHP RDT&E appropriations to fund approximately three or four (3 or 4) 
FY21 DMRDP JPC_6/CCCRP ERC Award applications. Funding of applications received is 
contingent upon the availability of Federal funds for this program as well as the number of 
applications received, the quality and merit of the applications as evaluated by scientific and 
programmatic review, and the requirements of the Government. Funds to be obligated on any 
award resulting from this funding opportunity will be available for use for a limited time 
period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 
funding opportunity will be funded with FY21, FY22, and FY23 funds, which will expire for 
use on September 30, 2027, September 30, 2028, and September 30, 2029, respectively.

Research Involving Human Anatomical Substances, Human Subjects, or Human 
Cadavers: All DoD-funded research involving new and ongoing research with human 
anatomical substances, human subjects, or human cadavers must be reviewed and approved by 
the U.S. Army Medical Research and Development Command (USAMRDC) Office of Research 
Protections (ORP), Human Research Protection Office (HRPO), prior to research 
implementation. This administrative review requirement is in addition to the local Institutional 
Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of 
submission is not required. Allow a minimum of 2 to 3 months for HRPO regulatory review 
and approval processes. Refer to the General Application Instructions, Appendix 1, and the 
Human Subject Resource Document available on the electronic Biomedical Research 
Application Portal (eBRAP) “Funding Opportunities & Forms” web page 
(https://ebrap.org/eBRAP/public/Program.htm) for additional information.

If the proposed research is cooperative (i.e., involving more than one institution), a written plan 
for single IRB review arrangements must be provided at the time of application submission or 
award negotiation. The lead institution responsible for developing the master protocol and 
master consent form should be identified and should be the single point of contact for regulatory 
submissions and requirements.

This Funding Opportunity may support applied or clinical research; however, clinical trials 
are not allowed under this Funding Opportunity. A clinical trial is defined as a research study 
in which one or more human subjects are prospectively assigned to one or more interventions
(which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

**Clinical Research is defined** as: (1) Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies; (2) Epidemiologic and behavioral studies; and (3) Outcomes research and health services research. **Note:** Studies that meet the requirements for IRB Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available.

**Use of DoD or Department of Veterans Affairs (VA) Resources:** If the proposed research involves access to active duty military patient populations and/or DoD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

**Research Involving Animals:** All DoD-funded research involving new and ongoing research with animals must be reviewed and approved by the USAMRDC ORP Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. **Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies.** Refer to the General Application Instructions, Appendix 1, for additional information.

**II.C. Eligibility Information**

**II.C.1. Eligible Applicants**

**II.C.1.a. Organization:** All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

**Government Agencies Within the United States:** Local, state, and Federal Government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this Program Announcement may be submitted by extramural and intramural organizations, these terms are defined below.

**Extramural Organization:** An eligible non-DoD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, Federal Government organization other than the DoD, and research institutes.
**Intramural DoD Organization:** A DoD laboratory, DoD military treatment facility, and/or DoD activity embedded within a civilian medical center. *Intramural Submission: Application submitted by a DoD organization for an intramural investigator working within a DoD laboratory or military treatment facility or in a DoD activity embedded within a civilian medical center.*

USAMRAA makes awards to eligible organizations, not to individuals.

**II.C.1.b. Principal Investigator**

An eligible Principal Investigator (PI), regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at [https://orcid.org/](https://orcid.org/).

**II.C.2. Cost Sharing**

Cost sharing/matching is not an eligibility requirement.

**II.C.3. Other**

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this Program Announcement.

**II.D. Application and Submission Information**

*Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).*

**Extramural Submission:**

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.
Intramural DoD Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

*Note: Applications from an intramural DoD organization or from an extramural Federal Government organization may be submitted to Grants.gov through a research foundation.*

II.D.1. Address to Request Application Package

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application (eBRAP.org) and full application (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to Table 1. Full Application Guidelines).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

*During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.*

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type will delay processing.

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.
All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

The applicant organization and associated PIs identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**
  
  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**
  
  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

  Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

  It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**
  
  Enter the name, organization, and role of all collaborators and key personnel associated with the application.

  FY21 DMRDP JPC-6/CCCRP ERCA Programmatic Panel members should not be involved in any pre-application or application. For questions related to panel members and pre-
applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

- **Tab 4 – Conflicts of Interest**

  List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

  *Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*

  - **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - **Research Plan:** Concisely state the ideas and rationale on which the proposed work is based. State the project’s hypotheses, objectives, and specific aims, and briefly describe the experimental approach.

  - **Personnel:** Briefly state the qualifications of the PI and key personnel to perform the described research project.

  - **Innovation, Impact and Relevance:** State explicitly how the proposed work is innovative and may improve trauma care. Describe the potential impact of this application to directly or indirectly benefit military Service members during multi-domain operations (MDO) and the public.

  - **Alignment with Focus Areas:** Identify and explain how the proposed work addresses at least one of the FY21 DMRDP JPC-6/CCCRP ERCA Focus Areas.

  - **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application *must be uploaded as individual files* and are limited to the following:

    - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
– List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

– Key Personnel Biographical Sketches (six-page limit per individual): All biographical sketches should be uploaded as a single combined file. Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

– Budget Summary: Upload as “BudgetSummary.pdf”. Complete the two-page Pre-Application Budget Summary Form (available for download in eBRAP) as instructed.

– Quad Chart: Upload as “QuadChart.pdf”. Complete the Quad Chart template, a one-page PowerPoint file that must be downloaded from the CDMRP eBRAP System at https://ebrap.org/eBRAP/public/Program.htm, and save, using Adobe Acrobat Reader, as a PDF file.

• Tab 6 – Submit Pre-Application

This tab must be completed for the pre-application to be accepted and processed.

Pre-Application Screening

• Pre-Application Screening Criteria

To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the JPC-6/CCCRP, pre-applications will be screened based on the following criteria:

○ Research Plan: How well the rationale, hypotheses, objectives, specific aims, and experimental approach support the research idea(s).

○ Alignment with Focus Areas: To what extent the proposed work addresses at least one of the FY21 JPC-6/CCCRP ERCA Focus Areas.

○ Innovation, Impact and Relevance: To what extent the study outcomes could improve trauma care. How well the proposed study is innovative and will directly or indirectly benefit military Service members during MDO and the public.

○ Personnel: To what extent the qualifications of the PI and key personnel are appropriate to perform the proposed research project.

• Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated in Section I, Overview of the Funding.
Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

II.D.2.b. Step 2: Full Application Submission Content

Applications will not be accepted unless notification of invitation has been received.

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each application submission must include the completed full application package for this Program Announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://www.grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

### II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the **same version** of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (https://www.grants.gov/web/grants/applicants/apply-for-grants.html) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

*Do not password protect any files of the application package, including the Project Narrative.*

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td></td>
</tr>
<tr>
<td>Download application package components for W81XWH-21-DMRDP-ERCA from Grants.gov (<a href="https://www.grants.gov">https://www.grants.gov</a>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</td>
<td>Download application package components for W81XWH-21-DMRDP-ERCA from eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>).</td>
</tr>
<tr>
<td>Extramural Submissions</td>
<td>Intramural DoD Submissions</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td><strong>Full Application Package Components</strong></td>
</tr>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td>Tab 1 – Summary: Provide a summary of the application information. Tab 2 – Application Contacts: This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
</tr>
<tr>
<td>Descriptions of each required file can be found under Full Application Submission Components:</td>
<td>Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</td>
</tr>
<tr>
<td>- Attachments</td>
<td>- Attachments</td>
</tr>
<tr>
<td>- Research &amp; Related Personal Data</td>
<td>- Key Personnel</td>
</tr>
<tr>
<td>- Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>- Budget</td>
</tr>
<tr>
<td>- Research &amp; Related Budget</td>
<td>- Performance Sites</td>
</tr>
<tr>
<td>- Project/Performance Site Location(s) Form</td>
<td></td>
</tr>
<tr>
<td>- Research &amp; Related Subaward Budget Attachment(s) Form</td>
<td>Tab 4 – Application and Budget Data: Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.</td>
</tr>
<tr>
<td>Extramural Submissions</td>
<td>Intramural DoD Submissions</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Application Package Submission</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Create a Grants.gov Workspace.</strong> Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.</td>
<td><strong>Submit package components to eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>).</strong></td>
</tr>
<tr>
<td><strong>Submit a Grants.gov Workspace Package.</strong> An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package at least <strong>24-48 hours prior to the close date</strong> to allow time to correct any potential technical issues that may disrupt the application submission. <strong>Note:</strong> If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID <strong>prior to</strong> the application submission deadline. <strong>Do not password protect any files of the application package, including the Project Narrative.</strong></td>
<td>Tab 5 – Submit/Request Approval Full Application: After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official by email. <strong>Do not password protect any files of the application package, including the Project Narrative.</strong></td>
</tr>
<tr>
<td><strong>Application Verification Period</strong></td>
<td></td>
</tr>
</tbody>
</table>

The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package may be modified **with the exception of the Project Narrative and Research & Related Budget Form.**
Extramural Submissions | Intramural DoD Submissions
--- | ---
**Further Information**

**Tracking a Grants.gov Workspace Package.** After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission.

Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

II.D.2.b.ii. Full Application Submission Components

- **Extramural Applications Only**

  **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications**

  **Attachments:**

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full application package may not exceed 200 MB.

  - **Attachment 1: Project Narrative (15-page limit):** Upload as “ProjectNarrative.pdf”. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

  Describe the proposed project in detail using the outline below.
- **Background:** Describe in detail the scientific rationale for the proposed study. Include a literature review and, if applicable, provide preliminary studies and/or data that support the scientific rationale and led to the development of the research project. The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. Establish the relevance and applicability of the proposed study and findings to the intent of the mechanism and address at least one of the FY21 JPC-6/CCCRP ERCA Focus Areas.

- **Objectives/Specific Aims/Hypothesis:** Provide a description of the purpose and objectives of the study with detailed specific aims and hypotheses.

**All proposed research:**

- Describe the experimental design, controls, methods, and analyses, and their integration into the project and how they will generate rigorous and reproducible results.

- Define the study variables and describe how they will be measured. Include a description of appropriate controls, endpoints to be used, and analyses to be performed and how they function to achieve the research objectives and the anticipated outcomes of the study.

- Describe the statistical plan as appropriate for the proposed research.

- Identify and describe potential problem areas in the proposed approach and alternative methods and approaches that will be employed to mitigate any risks that are identified.

- Applications that include research on animal models are also required to submit Attachment 8, Animal Research Plan.

**For research involving human subjects:**

- Describe the population(s) of interest and how they relate to the research objectives.

- Describe the methods that will be used to recruit a sample of human subjects from the accessible population (e.g., convenience, simple random, stratified random).

- Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures), if applicable. Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).

- Specify the approximate number of human subjects that will be enrolled. If multiple study sites are involved, state the approximate number to be enrolled.
at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.

- **Personnel:** Describe how the composition, background, expertise, levels of effort, and record of success of the research/study team personnel (e.g., study coordinator, statistician, etc.) are appropriate to ensure success of the proposed research.

- **Attachment 2: Supporting Documentation:** Combine and upload as a single file named “Support.pdf”. Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

*There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.*

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

- Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- Letters of Organizational Support: Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement, such as those from members of Congress, do not impact application review or funding decisions.
Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.


- Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.

Use of DoD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active duty military populations and/or DoD resources or databases.

Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

- Background: Present the ideas and reasoning behind the proposed work.

- Objective/Hypothesis: State the objective to be reached/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.

- Specific Aims: State the specific aims of the study.
Study Design: Briefly describe the study design including appropriate controls. For studies enrolling human subjects, describe the population and enrollment targets. For animal studies, include a description of the animal model.

Impact: Identify the FY21 JPC-6/CCCRP ERCA Focus Area(s) to be addressed and briefly describe how the proposed research will impact trauma care.

Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”. The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

- Lay abstracts should be written using the outline below. Do not duplicate the technical abstract.
- Describe the objectives and rationale for the research in a manner that will be readily understood by readers without a science or medical background.
- Identify the FY21 JPC-6/CCCRP ERCA Focus Area(s) to be addressed.
- Describe the potential research and clinical applications, benefits, and risks.
- Describe the projected timeline to achieve the expected patient-related outcome.
- What types of patients will it help, and how will it help them?

Attachment 5: Statement of Work (five-page limit): Upload as “SOW.pdf”. The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). Recommended strategies for assembling the SOW can be found at https://ebrap.org/eBRAP/public/Program.htm.

For the FY21 DMRDP JPC-6/CCCRP ERCA mechanism, refer to the “Suggested SOW Strategy Generic Research” document for guidance on preparing the SOW and use the blank SOW format titled “Suggested SOW Format”. The SOW must be in PDF format prior to attaching.

Attachment 6: Impact and Military Benefit Statement (two-page limit): Upload as “Impact.pdf”. Explain the proposed research project’s potential impact and military benefit as follows:

- Innovation¹: Describe how the proposed research is innovative.

¹ For this Program Announcement, innovation refers to value created through the application of existing and novel ideas and products. The next logical step or continuation of an existing idea or product is not innovative.
- **Short-Term Impact**: Describe how the anticipated short-term outcome(s) will optimize survival and recovery in highly mobile, austere, and extreme environments where evacuation capabilities may be significantly delayed or unavailable.

- **Long-Term Impact**: Describe the anticipated research outcomes or long-term vision that will impact the development of medical solutions for Service members and the public. Describe how the proposed materiel or knowledge product represents an improvement to currently available pharmacologic agents, devices, or clinical guidance (as applicable).
  - Compare the proposed materiel or knowledge product to currently available pharmacologic agents, devices, or clinical guidance, if applicable.

- **Military Benefit**: Clearly articulate how the proposed research will have the potential to enable increased levels of care en route, mitigate negative effects of transportation or environmental extremes, provide patient care for longer time periods when delayed evacuation exceeds available capability and/or capacity, and extend provider capabilities in order to care for larger numbers of casualties.

- **Public Purpose**: Concisely describe how this research can benefit the general public.

- **Challenges**: Describe potential issues that might limit the impact of the proposed research and strategies that may be employed to overcome those issues.

- **Attachment 7: Transition Plan (three-page limit): Upload as “Transition.pdf”**: Provide information on the methods and strategies proposed to move the anticipated research outcomes to the next phase of research or delivery to the military or civilian market/clinical practice after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below.
  - Using Appendix 2 as a guide, describe the maturity of the product and provide the current and projected research technology or knowledge readiness level (as appropriate) at the end of the proposed.
  - Details of the funding strategy that will be used to bring the outcomes to the next level (e.g., specific potential industry partners, specific funding opportunities/mechanisms to be pursued).
  - A description of collaborations and other resources that will be used to provide continuity of development.
  - For Knowledge Products, a description of collaborations and other resources that will be used to provide continuity of development, including proposed development or modification of clinical practice guidelines and recommendations, provider training.
materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications.

- A brief schedule and milestones for transitioning the intervention to the next phase of development (i.e., next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the U.S. Food and Drug Administration [FDA]).

- Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the Government’s ability to access such products or technologies in the future.

- A risk analysis for cost, schedule, manufacturability, and sustainability, if applicable.

○ Attachment 8: Animal Research Plan (if applicable; required for all studies utilizing animals; five-page limit per animal study): Upload as “AnimRschPln.pdf”.

When the proposed study involves animals, the applicant is required to submit a summary describing the animal research that will be conducted. Applicants should not submit a verbatim replica of the protocol(s) to be submitted to the IACUC as the Animal Research Plan. The Animal Research Plan should address the following points for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.

- Summarize the procedures to be conducted. Describe how the study will be controlled.

- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.

- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.

- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

- Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

○ Attachment 9: Data Management (if applicable; required for all studies recruiting human subjects; no page limit): Upload as “Data_Manage.pdf”. The Data Management attachment should include the components listed below:
Describe all methods used for data collection to include the following:

- **Identifiers:**
  - Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.

- **Confidentiality:**
  - Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
  - Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DoD are eligible to review study records.
  - Address requirements for reporting sensitive information to state or local authorities.

- **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) are required.

- **Data reporting:** Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

- **Sharing Study Results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.

- **Laboratory Evaluations:**
  - **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.
• **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

• **Storage:** Describe specimen storage, to include location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

• **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

  o **Attachment 10: Human Subject Recruitment and Safety Procedures (if applicable; required for all studies recruiting human subjects; no page limit):** Upload as “HumSubProc.pdf”. The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.

    – **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts at each study site. Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual goals. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical studies (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment or poor retention. Identify ongoing clinical studies that may compete for the same patient population and how they may impact enrollment progress. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender. *For clinical studies proposing to include military personnel, refer to the General Application Instructions, Appendix 1, for more information.*

    – **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical study. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

    – **Women and Minorities in the Study:** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote
equity both in assuming the burdens and in receiving the benefits of human subjects research. Describe the strategy for the inclusion of women and minorities in the clinical study appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnicity, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The suggested Inclusion Enrollment Report format is a one-page fillable PDF form, which can be downloaded from eBRAP at https://ebrap.org/eBRAP/public/Program.htm.

- **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).

  - Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.

  - If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.

  - Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

- **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.

  - *For the proposed study, provide a draft, in English, of the Informed Consent Form.*

  - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the study.

  - Include information regarding the timing and location of the consent process.

  - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.

  - Address how privacy and time for decision-making will be provided and whether the potential human subject will be allowed to discuss the study with anyone before making a decision.
Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.

Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: In compliance with 10 USC 980 (https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf), the application must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical study. If applicable, refer to the General Application Instructions, Appendix 1, for more information.

Assent. If minors or other populations that cannot provide informed consent are included in the proposed clinical study, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

- Screening Procedures: List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Note: Some screening procedures may require a separate consent or a two-stage consent process.

- Risks/Benefits Assessment:
  - Foreseeable risks: Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is exposed to as a result of participation in the clinical study. Consider psychological, legal, social, and economic risks as well as physical risks. Consider how the proposed clinical study might affect the daily lives of the individual human subjects participating in the study. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.

  - Risk management and emergency response:
    - Appropriate to the study’s level of risk, describe how safety monitoring and reporting to the IRB and FDA (if applicable) will be managed and conducted.
    - Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.

Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).

Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.

Potential benefits: Describe known and potential benefits of the study to the human subjects who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.

Attachment 11: Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP (https://ebrap.org/eBRAP/public/Program.htm). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

Attachment 12: Suggested Collaborating DoD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”. If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DoD Military Facility Budget Format”, available for download on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

Extramural and Intramural Applications

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC A§1681 et seq.), the DoD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

Research & Related Personal Data: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via
Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- PI Biographical Sketch (six-page limit): Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The National Institutes of Health Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

  For extramural submissions, refer to the General Application Instructions, Section III.A.4 for detailed information.

  For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

- Key Personnel Biographical Sketches (six-page limit each): Upload as “Biosketch_LastName.pdf”.

- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

- Extramural Applications Only

  Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.
Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

Intramural DoD Collaborator(s): Complete the “Suggested Collaborating DoD Military Facility Budget Format” and upload to Grants.gov attachment form as Attachment 12. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DoD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant organization’s Entity registration in SAM well in advance of the application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the Federal awarding agency is ready to make a Federal award, the Federal awarding agency may determine that the applicant is not qualified to receive a Federal award and use that determination as a basis for making a Federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

Announcement of Transition to SAM-Generated Unique Entity Identifier (UEI): Through April 2022, a transition from DUNS to the SAM-generated UEI will occur. Refer to the General Application Instructions, Section III.1, DUNS Number, for more information on the transition and timing.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific Program Announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly
recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement. **If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline.** The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

**Extramural Submission:** The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, **with the exception of the Project Narrative and Budget Form,** may be modified.

**Intramural DoD Submission:** After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, **with the exception of the Project Narrative and Budget Form,** may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

**For All Submissions:** Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

**II.D.5. Funding Restrictions**

The maximum period of performance is 4 years.

The anticipated total costs budgeted for the entire period of performance will not exceed **$1.4M.** If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding **$1.4M** total costs or using an indirect cost rate exceeding the organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

For this award mechanism, direct costs must be requested for:

- **Interim (In-Progress) Review (IPR):** Travel costs for the PI(s) for attendance and participation in at least one 2-day IPR should be requested.
• **Military Health System Research Symposium (MHSRS):** Travel costs for the PI(s) to present project information or disseminate project results at the DoD-sponsored MHSRS meeting during the period of performance year 3 should be requested. For planning purposes, it should be assumed that the meeting will be held in the Central Florida Region. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all inclusive):

• Travel in support of multidisciplinary collaborations.

• Costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel costs to scientific/technical meeting(s) is to present project information or disseminate project results from the FY21 DMRDP JPC-6/CCCRP ERC.

Must not be requested for:

• Clinical trial costs

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DoD or other Federal agency is not allowed except under very limited circumstances. Funding to intramural DoD and other Federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.*

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

• **Research Strategy and Feasibility**
  - How well the literature review and preliminary studies and data support the scientific rationale of the research project and led to the development of the research project.
○ How relevant and applicable the proposed research and findings are to at least one of the FY21 DMRDP JPC-6/CCCRP ERCA Focus Areas.

○ How well the objectives/specific aims and hypotheses are described.

○ How well the experimental design, controls, methods, and analyses are integrated into the project and how they will generate rigorous and reproducible results.

○ How well the study is designed to achieve the research objectives and the anticipated outcomes of the study, including the choice of model/human subject population (as applicable), appropriate controls, endpoints to be used, and analyses to be performed.

○ How well the application acknowledges potential problems and addresses alternative approaches.

○ Whether the research can be completed within the proposed period of performance.

○ For clinical research involving human subjects:
  – How well the application describes the population(s) of interest, demonstrates access to these populations, and has a viable plan for recruitment, consent, screening, and retention of appropriate subjects.
  – How well the stated inclusion/exclusion criteria take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population.
  – Whether the strategy for the inclusion of women and minorities is appropriate to the objectives of the study.
  – Whether the distribution of the proposed enrollment on the basis of sex/gender, race, and/or ethnicity is appropriate for the proposed research.

• Impact

○ To what degree the proposed research is innovative.

○ To what extent the short-term outcome(s) of the proposed research will optimize survival and recovery in highly mobile, austere, and extreme environments where evacuation capabilities may be significantly delayed or unavailable.

○ To what extent the anticipated research outcomes or long-term vision of the proposed research may impact the development of medical solutions for Service members and the public.

○ If applicable, to what degree the proposed materiel or knowledge product represents an improvement to currently available pharmacologic agents, devices, or clinical guidance (as applicable).
• Personnel
  ○ Whether the composition of the research or study team (e.g., study coordinator, statistician) is appropriate.
  ○ How the levels of effort by the PI and other key personnel are appropriate to ensure success of the proposed research.
  ○ How the study team’s background, expertise, and record(s) of accomplishment demonstrate their ability to accomplish the proposed work.

• Ethical Considerations (for studies recruiting human subjects)
  ○ How the level of risk to human subjects is minimized, and how the safety monitoring and reporting plan is appropriate for the level of risk.
  ○ To what degree privacy issues are appropriately considered.
  ○ To what degree the process for seeking informed consent is appropriate.

• Statistical Plan
  ○ To what degree the statistical plan, including sample size projections/power analysis, blinding, randomization, and data analysis plan are adequate for the study and all proposed correlative studies.
  ○ If applicable, whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.

• Transition Plan
  ○ Whether the funding strategy described to move the anticipated research outcome(s) to the next phase of research or delivery to the military or civilian market/clinical practice is appropriate.
  ○ Whether appropriate collaborations and other resources for providing continuity of development are established and/or well described.
  ○ How the schedule and milestones for transitioning the outcome(s) to the next phase of development (i.e., next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the FDA) are appropriate.
  ○ If applicable, how well the potential risk analysis for cost, schedule, manufacturability, and sustainability is developed.
  ○ How well the application identifies intellectual property ownership, describes any appropriate intellectual and material property plan among participating organizations (if
applicable), and addresses any impact of intellectual property issues on product development and subsequent Government rights and ability access to such products or technologies supported by this Funding Opportunity.

In addition, the following **unscored** criteria will also contribute to the overall evaluation of the application:

- **Budget**
  - Whether the **total** costs exceed the allowable total costs as published in the Program Announcement.
  - Whether the budget is appropriate for the proposed research.

- **Environment**
  - To what degree the scientific environment and the accessibility of institutional/organizational resources support the proposed research requirements (including collaborative arrangements).
  - How the quality and extent of institutional/organizational support are appropriate for the proposed project.

- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influence the review.

**II.E.1.b. Programmatic Review**

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers

- Relevance to the mission of the DHP and JPC-6/CCCRP, as evidenced by the following:
  - Adherence to the intent of the award mechanism
  - Program portfolio composition
  - Relative impact and innovation
  - Relative military benefit
II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC, on behalf of the DHA and the OASD(HA). The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.army.mil/about/2tierRevProcess. An information paper describing the funding recommendations and review process for the award mechanisms for the FY21 DMRDP JPC-6/CCCRP will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the Federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.88, over the period of performance, the Federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a Federal awarding agency previously entered and is currently available in FAPIIS.

The Federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under Federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.
II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY21 funds are anticipated to be made no later than September 30, 2022. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI’s organization.

Pre-Award Costs: An institution of higher education, hospital, or other non-profit organization may, at its own risk and without the Government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the Government to the expenditure of funds. No commitment on the part of the Government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document.

Federal Government Organizations: Funding made to Federal Government organizations (to include intramural DoD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

II.F.1.a. PI Changes and Award Transfers

Unless otherwise restricted, changes in PI will be allowed at the discretion of the Grants Officer, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.
II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this Program Announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D General Terms and Conditions; the USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations: Addendum to the DoD R&D General Terms and Conditions; and the USAMRAA General Research Terms and Conditions with For-Profit Organizations for further information.

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.

Annual progress reports as well as a final progress report will be required.

The Award Terms and Conditions will specify if more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline if and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

Inclusion Enrollment Reporting Requirement (only required for clinical research studies): Enrollment on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final technical report. The suggested Inclusion Enrollment Report format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from this Program Announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have Federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10,000,000 are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a Federal award. Recipients are
required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to Program Announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the Program Announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this Program Announcement should refer to the Program name, the Program Announcement name, and the Program Announcement version code 601a. The Program Announcement numeric version code will match the General Application Instructions version code 601.

II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:
II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Attachment 7, Transition Plan, is missing.

*For applications involving animal research:*

- Attachment 8, Animal Research Plan, is missing.

*For applications recruiting human subjects:*

- Attachment 9, Data Management, is missing.
- Attachment 10, Human Subject Recruitment and Safety Procedures, is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY21 DMRDP JPC-6/CCCRP ERCA Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. *A list of the FY21 DMRDP JPC-6/DMRDP ERCA Programmatic Panel members can be found at https://cdmrp.army.mil/dmrdp/panels/21jpc_6_erca.*
- The application fails to conform to this Program Announcement description.
• Proposed research is not aligned to at least one of the Focus Areas for the FY21 DMRDP JPC-6/CCCRP ERCA.

• Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

• To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY21, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.army.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies may be administratively withdrawn.

• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

• Applications from extramural organizations, including non-DoD Federal agencies, received through eBRAP may be withdrawn.

• Applications submitted by an intramural DoD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• Submission of the same research project to different funding opportunities within the same program and fiscal year.

• The invited application proposes a different research project than that described in the pre-application.

• A clinical trial is proposed.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>(extramural submissions only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2)</td>
<td>Complete tabs as instructed</td>
<td></td>
</tr>
<tr>
<td>(intramural submissions only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attachments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact and Military Benefit Statement: Upload as Attachment 6 with file name “Impact.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan: Upload as Attachment 7 with file name “Transition.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal Research Plan: Upload as Attachment 8 with file name “AnimRsChPln.pdf” (if applicable; required for all studies utilizing animals)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 9 with file name “Data_Manage.pdf” (if applicable; required for all studies recruiting human subjects)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Subject Recruitment and Safety Procedures: Upload as Attachment 10 with file name “HumSubProc.pdf” (if applicable; required for all studies recruiting human subjects)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Representations (extramural submissions only): Upload as Attachment 11 with file name “RequiredReps.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suggested Collaborating DoD Military Facility Budget Format: Upload as</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Completed</td>
</tr>
<tr>
<td>------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Attachment 12 with file name “MFBudget.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Personal Data</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Budget (intramural submissions only)</td>
<td>Suggested DoD Military Budget Format, including justification</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
</tbody>
</table>
# APPENDIX 1: ACRONYM LIST

<p>| ACOS/R&amp;D | Associate Chief of Staff for Research and Development |
| ACURO   | Animal Care and Use Review Office |
| CDMRP   | Congressionally Directed Medical Research Programs |
| CFR     | Code of Federal Regulations |
| DHA     | Defense Health Agency |
| DHP     | Defense Health Program |
| DoD     | Department of Defense |
| DoDGARs | Department of Defense Grant and Agreement Regulations |
| DMRDP   | Defense Medical Research and Development Program |
| DUNS    | Data Universal Numbering System |
| eBRAP   | Electronic Biomedical Research Application Portal |
| EC      | Ethics Committee |
| ERC     | En Route Care |
| ERCA    | En Route Care Award |
| ET      | Eastern Time |
| FAD     | Funding Authorization Document |
| FAPIIS  | Federal Awardee Performance and Integrity Information System |
| FDA     | Food and Drug Administration |
| FY      | Fiscal Year |
| HRPO    | Human Research Protection Office |
| IACUC   | Institutional Animal Care and Use Committee |
| IPR     | In-Progress Review |
| IRB     | Institutional Review Board |
| LAR     | Legally Authorized Representative |
| M       | Million |
| MDO     | Multi-Domain Operations |
| MHS     | Military Health System |
| MIPR    | Military Interdepartmental Purchase Request |
| NIH     | National Institutes of Health |
| OASD(HA) | Office of the Assistant Secretary of Defense for Health Affairs |
| ORCID   | Open Researcher and Contributor ID, Inc. |
| ORP     | Office of Research Protections |
| PI      | Principal Investigator |
| RDT&amp;E   | Research, Development, Test, and Evaluation |
| SAM     | System for Award Management |
| SAR     | Search and Rescue |
| SOW     | Statement of Work |
| STEM    | Science, Technology, Engineering, and/or Mathematics |
| UEI     | Unique Entity Identifier |
| URL     | Uniform Resource Locator |
| USAMRAA | U.S. Army Medical Research Acquisition Activity |</p>
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>USAMRDC</td>
<td>U.S. Army Medical Research and Development Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>VA</td>
<td>Department of Veterans Affairs</td>
</tr>
</tbody>
</table>
APPENDIX 2: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS

Technology Readiness Levels (TRLs): TRLs are used to categorize the product maturity of materiel solutions. The DoD’s Technology Readiness Assessment (TRA) Deskbook, is a reference for systematic assessment of technical maturity of relevant materiel solutions. For biomedical applications, Biomedical TRL definitions and descriptions have been developed which account for regulatory context for technology maturity and intended context of use. Information on Biomedical TRLs can be found in Appendix E of the DoD TRA Deskbook (July 2009, [https://apps.dtic.mil/docs/citations/ADA524200](https://apps.dtic.mil/docs/citations/ADA524200)).

Knowledge Readiness Levels (KRLs): The scientific maturity of knowledge products resulting from biomedical research are not assessed in the same manner as materiel solutions. At the request of the U.S. Army Medical Research and Development Command, the Rand Corporation developed and released a framework to assess the relative scientific maturity of knowledge products. This process is described in a 2019 Rand Corporation Report ([https://www.rand.org/pubs/research_reports/RR2127.html](https://www.rand.org/pubs/research_reports/RR2127.html)). The figures below represent a quick reference guide for assessing KRLs for knowledge products.

**Step 1: Determine the Knowledge Product (KP):**

- **KRL 9:** Ratings are given to KPs resulting from research designed to emphasize external validity (generalizability) of knowledge for use in a specified real world application context. This research often addresses a policy question, asking, “How does it compare to usual practice?” To achieve a rating of KRL 9, the KP must be based on valid replicated KRL 4-6 research. Examples include:
  - Battlefield intervention
  - Primary care screener
  - Workplace prevention
  - Systematic reviews of KRL 7-9 research
  - Systematic reviews to inform creation of practice guidelines and study of a guideline

- **KRL 6:** KRL 4-6 ratings are given to KPs that seek to generate applied knowledge to eventually perform a non-research related function or to inform understanding of an application or tool. KRL 4-6 research often asks questions such as “Can the application work under ideal research conditions?” and “(if the application can work), how does it work?” To achieve a rating of KRL 4-6, the KP must be based on valid, replicated KRL-3 research. Examples include:
  - Applications that prevent, screen/diagnose, or treat illness
  - Systematic reviews that summarize KRL-4-6 research

- **KRL 3:** KRL 1-3 provide the scientific foundation for KP development toward practical application. These KPs are the outputs of health research that seeks basic mechanisms rather than applications and tends to be theoretical or conceptual, often (but not always) comprising laboratory, descriptive, or exploratory studies. Examples include:
  - Animal research
  - Non-Clinical laboratory research
  - Descriptive epidemiology
  - Systematic reviews of KRL-1-3 research

- **KRL 2:**

- **KRL 1:**